000303371 001__ 303371
000303371 005__ 20250822113120.0
000303371 0247_ $$2doi$$a10.1530/ERC-25-0165
000303371 0247_ $$2pmid$$apmid:40748172
000303371 0247_ $$2ISSN$$a1351-0088
000303371 0247_ $$2ISSN$$a1479-6821
000303371 0247_ $$2altmetric$$aaltmetric:180136439
000303371 037__ $$aDKFZ-2025-01620
000303371 041__ $$aEnglish
000303371 082__ $$a610
000303371 1001_ $$00000-0003-0244-3510$$aMathew, A.$$b0
000303371 245__ $$aLenvatinib as Salvage Therapy in Advanced and Progressive GI-NET.
000303371 260__ $$aBristol$$bSoc. for Endocrinology$$c2025
000303371 3367_ $$2DRIVER$$aarticle
000303371 3367_ $$2DataCite$$aOutput Types/Journal article
000303371 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755855041_6500
000303371 3367_ $$2BibTeX$$aARTICLE
000303371 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303371 3367_ $$00$$2EndNote$$aJournal Article
000303371 500__ $$a2025 Aug 20;32(8):e250165
000303371 520__ $$aThe efficacy of lenvatinib in treating gastrointestinal neuroendocrine tumors (GI-NET) has been explored in preclinical studies and early-phase clinical trials but real-world data remains limited. Data of sixteen patients (median age 65 years; 62.5% female) with advanced and progressive GI-NET who were treated with lenvatinib at the ENETS Center, University Hospital Essen, between 07/2019 and 02/2024 were analyzed. Patients had received all other approved therapies and showed progression within two months. Salvage therapy with lenvatinib was initiated after approval by health insurance. Most NETs originated in the small intestine (94%) with a median Ki-67 index of 3.5%. Before lenvatinib, patients had received a median of four lines of treatment (range 3-7), including somatostatin analogues (100%), everolimus (100%), chemotherapy (25%) and PRRT (88%). Surgery of the primary and/or metastatic lesions was performed in 81% and ablative therapies in 38%. The median time between NET diagnosis and initiation of lenvatinib was 100 months. The overall response rate on salvage therapy was 29% and the clinical benefit rate 100%. Median progression-free survival (PFS) on lenvatinib was 10 months and median overall survival (OS) after initiation of lenvatinib reached 113 months. Hypertension was associated with significantly longer PFS (24.5 months, p=0.007), whereas weight loss correlated with shorter PFS (4 months, p=0.0032). In this retrospective single-center case analysis, lenvatinib demonstrated promising results in heavily pre-treated and rapidly progressing GI-NET. With an OS of 9.4 years after start of salvage therapy, these results highlight the value of lenvatinib as a therapeutic option for advanced GI-NET patients with otherwise limited treatment alternatives.
000303371 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000303371 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303371 650_7 $$2Other$$aNET
000303371 650_7 $$2Other$$aTKI
000303371 650_7 $$2Other$$alenvatinib
000303371 650_7 $$2Other$$aneuroendocrine tumors
000303371 7001_ $$aCapdevila, J.$$b1
000303371 7001_ $$aUnger, N.$$b2
000303371 7001_ $$0P:(DE-HGF)0$$aFendler, W.$$b3
000303371 7001_ $$aTheurer, S.$$b4
000303371 7001_ $$aWeber, F.$$b5
000303371 7001_ $$aFuhrer, D.$$b6
000303371 7001_ $$aLahner, H.$$b7
000303371 773__ $$0PERI:(DE-600)2010895-3$$a10.1530/ERC-25-0165$$gp. ERC-25-0165$$n8$$pe250165$$tEndocrine related cancer$$v32$$x1351-0088$$y2025
000303371 909CO $$ooai:inrepo02.dkfz.de:303371$$pVDB
000303371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000303371 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000303371 9141_ $$y2025
000303371 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bENDOCR-RELAT CANCER : 2022$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-17
000303371 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-17
000303371 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000303371 980__ $$ajournal
000303371 980__ $$aVDB
000303371 980__ $$aI:(DE-He78)ED01-20160331
000303371 980__ $$aUNRESTRICTED